A recent study reveals that patients who come off new GLP-1 drugs like Mounjaro or Wegovy can put back on lost weight at a significantly accelerated pace than those who stop traditional diet and exercise programs.
Published data in a prominent health publication shows that while overweight people frequently drop substantial amounts of their body weight while undergoing treatment, the mass is regained at an average rate of nearly a kilo each month once they quit.
"Individuals purchasing these medications must be aware of the danger of fast rebound weight gain when the medication concludes," cautioned researcher Dr. Susan Jebb.
That rate of recovery suggests a reversion to starting mass in about 18 months.
Weighing Therapies
The research, which examined dozens of trials involving thousands of participants, compared the results of GLP-1 agonists with conventional dieting.
Researchers emphasize that people who lose weight through lifestyle changes alone usually experience a slower weight regain—around 0.1 kg a month—once they finish.
Explaining the Fast Rebound
Experts propose the way of the drugs accounts for the heightened rebound.
GLP-1 drugs mimic a natural hormone called GLP-1, which moderates hunger.
"Sustained high doses of the hormone concentrations far above than the body's typical production might result in the body to generate a reduced amount of its own natural GLP-1, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a nutrition expert.
"Stopping of this hormone supplement leads to hunger is unsuppressed, making excessive eating far more likely."
A Chronic Disease?
Health authorities advise the jabs for people with obesity-related health risks, alongside recommended diet and exercise modifications.
Professionals say that, given the likelihood of weight regain, the therapy should be considered ongoing.
This opinion is echoed by pharmaceutical companies, who note that the results "emphasize the long-term nature of excess weight," similar to managing diseases like diabetes.
User Testimonies
Individuals who have discontinued the jabs explain a intense return of hunger.
"It was like a switch activating and I was suddenly starving," said an individual.
The struggle is worsened if users have not developed sustainable lifestyle or habit modifications during therapy.
Significant Use
Figures show that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with interest remaining high.
- Adoption is higher among women compared to males.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion access the medications through private prescriptions rather than the NHS.
Ultimately, clinicians emphasize that while GLP-1 drugs are effective agents for weight loss, they are not a permanent solution and long-term success likely depends on ongoing lifestyle support.
